PMID: 9191528Jun 15, 1997Paper

A phase II trial of methotrexate, vinblastine, doxorubicin, and cisplatin in the treatment of metastatic carcinoma of the uterine cervix

Cancer
C A PapadimitriouS Michalas

Abstract

Patients with metastatic carcinoma of the uterine cervix have limited survival. Thus, new chemotherapeutic agents and combinations are needed to improve patient outcome. Twenty-seven patients with Stage IV primary or recurrent carcinoma of the uterine cervix were assigned to chemotherapy treatment at 4-week intervals with methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC). The treatment was comprised of methotrexate, 30 mg/m2 administered intravenously (i.v.) on Days 1, 15, and 22; vinblastine, 3 mg/m2 i.v. on Days 2, 15, and 22; doxorubicin, 30 mg/m2 i.v. on Day 2; and cisplatin, 70 mg/m2 i.v. on Day 2. Granulocyte-colony stimulating factor (G-CSF) was given subcutaneously on Days 6-10 at a dose of 5 micrograms/kg. After a median of 4 cycles (a maximum of 6 in responders), the authors observed objective responses in 14 patients (52%), including 3 complete responses (11%) and 11 partial responses (41%). Median overall survival was 11 months (range, 4-15+ months), and median progression free survival of the responders was 8 months (range, 6-15+ months). Toxicity was acceptable and included neutropenia, alopecia, vomiting, and stomatitis. MVAC is an active regimen in the treatment of patients with advanced or recurrent ...Continue Reading

References

Dec 1, 1990·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·W M Hryniuk, M Goodyear
Mar 1, 1989·Journal of the National Cancer Institute·E J BuxtonD M Luesley
Nov 1, 1988·Computer Methods and Programs in Biomedicine·N Campos-Filho, E L Franco
Feb 1, 1987·Seminars in Oncology Nursing·T E Schulheiss
Jan 1, 1981·Cancer·A B MillerA Winkler
Jan 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A M MuradJ C Ribalta
Sep 1, 1994·Current Opinion in Oncology·J P Neijt
May 1, 1993·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·J.B. Vermorken

❮ Previous
Next ❯

Citations

Sep 22, 2005·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·L H LêA M Oza
Jun 29, 2006·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·K SerkiesR Dziadziuszko
Jun 26, 2012·Cancer Treatment Reviews·Giannis MountziosChristos A Papadimitriou
Jul 29, 2008·Cancer Treatment Reviews·D PectasidesE Pectasides
May 20, 2009·Cancer·Sujana MovvaClaire Verschraegen
Jul 10, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Harry J Long
May 25, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Harry J LongUNKNOWN Gynecologic Oncology Group Study
Mar 29, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jeffrey D BlossJo Benda
Aug 9, 2006·Current Opinion in Oncology·David H Moore
Dec 21, 2000·Current Oncology Reports·J D Bloss
Oct 14, 2005·Current Oncology Reports·Krishnansu S Tewari, Bradley J Monk
Jan 17, 2014·Expert Review of Anticancer Therapy·Laurie M Elit, Hal Hirte
Jul 1, 2014·Current Opinion in Obstetrics & Gynecology·Ramez N Eskander, Krishnansu S Tewari
Mar 10, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C A PapadimitriouM A Dimopoulos
Mar 10, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S PignataS Tramontana

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.